22.06.2012
MagForce enters into preclinical research agreement to investigate NanoTherm® therapy in the gastrointestinal cancer field in the USA
Berlin, Germany, June 22, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that the Company has entered into a pre-clinical research agreement with Mayo Clinic (Rochester, MN), a leading US medical ...
31.05.2012
MagForce signs distribution agreement with Turkish medical product distribution company Tek Grup
Berlin, Germany, May 31, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, and Tek Grup Inc., a Turkish medical product distribution company, announced today the signing of an exclusive distribution agreement.
22.05.2012
MagForce signs distribution agreement with leading Russian medical device distribution company DELRUS
Market entry of NanoTherm® therapy in Russia expected for 2013; extension to number of CIS states to followDELRUS responsible for market approval in these territoriesFirst step for internationalization of NanoTherm® therapy Berlin, Germany, May 22, 2012 – MagForce AG (Frankfurt, XETRA: MF6), ...
07.05.2012
MagForce to Present at Entry & General Standard Conference 2012 in Frankfurt
Berlin, Germany, May 07, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine for oncology, announced today that Dr Andreas Jordan, Executive Board, will deliver a presentation on the Company at the Entry & General Standard Conference ...
03.05.2012
MagForce AG hires Christian von Volkmann as Head of Finance
von Volkmann leads Financial Department with immediate effectMagforce’s Financial Department will again be headed up by a competent leaderBerlin, Germany, May 3, 2012 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced ...
26.03.2012
MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012
Greater emphasis on clinical development to provide key physicians with access to NanoTherm therapyStart of post marketing glioblastoma study Q3 2012 to support expanded market acceptance with leading medical expertsEnhanced activities for international partnerships and initiation of discussions ...
29.02.2012
MagForce AG Successfully Completes Capital Increase
Announcement in accordance with section 17 para. 2 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market on the Frankfurt Stock ExchangeBerlin, February 29, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on ...
